e-learning
resources
Stockholm 2007
Monday 17.09.2007
Pulmonary infections in the immunocompetent and immunocompromised host
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Vancomycin MICs for respiratory isolates of community-associated MRSA and hospital-associated MRSA
R. Nakamatsu, M. Allen, T. Weimkem, B. Moffett, M. Zervos, J. A. Ramirez (Louisville, KY, Detroit, MI, United States Of America)
Source:
Annual Congress 2007 - Pulmonary infections in the immunocompetent and immunocompromised host
Session:
Pulmonary infections in the immunocompetent and immunocompromised host
Session type:
Thematic Poster Session
Number:
2575
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Nakamatsu, M. Allen, T. Weimkem, B. Moffett, M. Zervos, J. A. Ramirez (Louisville, KY, Detroit, MI, United States Of America). Vancomycin MICs for respiratory isolates of community-associated MRSA and hospital-associated MRSA. Eur Respir J 2007; 30: Suppl. 51, 2575
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Clinical outcomes of patients with hospital-acquired pneumonia due to community-associated methicillin resistant
staphylococcus aureus
(CA-MRSA)
Source: Eur Respir J 2007; 30: Suppl. 51, 407s
Year: 2007
Community-associated methicillin-resistant
staphylococcus aureus
(CA-MRSA) as a cause of hospital-acquired pneumonia (HAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 410s
Year: 2007
What is MRSA?
Source: Eur Respir J 2009; 34: 1190-1196
Year: 2009
Predictive factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in a MRSA screening protocol.
Source: International Congress 2018 – Difficult-to-treat respiratory infections
Year: 2018
Staphlococcus aureus
: susceptibility to antibacterial drugs and rate of MRSA
Source: Eur Respir J 2006; 28: Suppl. 50, 788s
Year: 2006
Treatment challenges in methicillin resistant
Staphylococcus aureus
infections
Source: Annual Congress 2006 - Methicillin resistant
Staphylococcus aureus
(MRSA): a real hospital-based pathogen?
Year: 2006
Molecular epidemiology and antimicrobial resistance of methicillin-resistant staphylococcus aureus isolated from nasal swab at intensive care unit
Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens
Year: 2008
Antibiotic susceptibility patterns of respiratory strains of Staphylococcus aureus in a Turkish university hospital
Source: Eur Respir J 2003; 22: Suppl. 45, 148s
Year: 2003
Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant
Staphylococcus aureus
Source: Annual Congress 2006 - Methicillin resistant
Staphylococcus aureus
(MRSA): a real hospital-based pathogen?
Year: 2006
Risk factors for methicillin-resistant Staphylococcus aureus isolation from serially obtained sputum in patients hospitalized with pneumonia
Source: Virtual Congress 2020 – Clinical challenges in pneumonia
Year: 2020
Significance of methicillin-resistant
staphylococcus aureus
in lower respiratory tract infections
Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens
Year: 2008
The efficacies of macrolides in a murine model of methicillin-resistant staphylococcus aureus hematogenous pulmonary infection
Source: Eur Respir J 2002; 20: Suppl. 38, 357s
Year: 2002
Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial
Source: Eur Respir J 2004; 23: 921-926
Year: 2004
Levofloxacin non-susceptible
streptococcus pneumoniae
in community-acquired respiratory infection; prevalence and risk factors
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
MRSA as a cause of community-acquired pneumonia
Source: Eur Respir J 2009; 34: 1013-1014
Year: 2009
Methicillin-resistant Staphylococcus aureus (MRSA) active screening in a Pulmonology department.
Source: International Congress 2018 – Clinical challenges in respiratory infection
Year: 2018
CusS-cusR mediate carbapenem-resistant Klebsiella pneumoniae resistant to tigecycline.
Source: International Congress 2019 – Clinical challenges in respiratory infection
Year: 2019
Emergence of penicillin resistant
Streptococcus pneumoniae
in Pakistan
Source: Eur Respir J 2005; 26: Suppl. 49, 639s
Year: 2005
Community-acquired pneumonia due to S. aureus
Source: Annual Congress 2011 - Aetiology, diagnosis and outcomes in community-acquired pneumonia
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept